SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Condition(s) studied
Investigational drug(s) / intervention(s)
SL-APO: Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an "ON" response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better "ON" response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode.
Study summary
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
Eligibility
Primary outcome measure(s)
- Identify the most frequent dose used after dose-adjustment — Up to 6 months
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SLAPO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und Neuromodulation | Berlin | Germany | Recruiting |
| Alexianer St. Joseph Berlin-Weißensee GmbH | Berlin | Germany | Suspended |
| Praxis für Neurologie | Berlin | Germany | Recruiting |
| Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für Neurologie | Bochum | Germany | Not Yet Recruiting |
| UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im Neurozentrum | Freiburg im Breisgau | Germany | Recruiting |
| Praxis für Neurologie und Psychiatrie | Fulda | Germany | Recruiting |
| Klinik am Tharandter Wald | Hetzdorf | Germany | Recruiting |
| Klinik für Neurologie und Neurologische Frührehabilitation | Osnabrück | Germany | Recruiting |
| Die Nerven Docs | Siegen | Germany | Recruiting |
| Neurologische Klinik Sorpesee | Sundern | Germany | Recruiting |
| Praxis für Neurologie und Geriatrie | Ulm | Germany | Recruiting |
| Neurologie am Funkerberg | Wusterhausen | Germany | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07145190 on ClinicalTrials.gov ↗ ← All trials in Germany